Loading...

You're on the old version of Simply Wall St. We will no longer be supporting this site, so we recommend you switch to our brand new platform.

Esperite

ENXTAM:ESP
Snowflake Description

Adequate balance sheet with weak fundamentals.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
ESP
ENXTAM
€2M
Market Cap
  1. Home
  2. NL
  3. Pharmaceuticals & Biotech
Company description

Esperite N.V., together with its subsidiaries, operates as a regenerative and predictive medicine company in the Netherlands, Spain, Italy, Switzerland, and internationally. The last earnings update was 283 days ago. More info.


Add to Portfolio Compare Print
  • Esperite has significant price volatility in the past 3 months.
ESP Share Price and Events
7 Day Returns
2.9%
ENXTAM:ESP
3.9%
NL Biotechs
3.5%
NL Market
1 Year Returns
-66.2%
ENXTAM:ESP
55.1%
NL Biotechs
-19.6%
NL Market
ESP Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Esperite (ESP) 2.9% -2.5% -23.9% -66.2% -97% -98.9%
NL Biotechs 3.9% 3.2% -8% 55.1% 95.2% 32.1%
NL Market 3.5% -3.9% -21.1% -19.6% -10.2% -9%
1 Year Return vs Industry and Market
  • ESP underperformed the Biotechs industry which returned 55.1% over the past year.
  • ESP underperformed the Market in Netherlands which returned -19.6% over the past year.
Price Volatility
Industry
5yr Volatility vs Market

ESP Value

 Is Esperite undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.

In this section, we usually try to help investors determine whether Esperite is trading at an attractive price based on the cash flow it is expected to produce in the future. But as Esperite has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.

This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis. You can see them here.

Show me the analysis anyway

INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Esperite. This is due to cash flow or dividend data being unavailable. The share price is €0.035.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Esperite's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Esperite's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
ENXTAM:ESP PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-06-30) in EUR Not available
ENXTAM:ESP Share Price ** ENXTAM (2020-04-08) in EUR €0.04
Europe Biotechs Industry PE Ratio Median Figure of 24 Publicly-Listed Biotechs Companies 43.07x
Netherlands Market PE Ratio Median Figure of 80 Publicly-Listed Companies 15.12x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Esperite.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to compare the PE ratio to the industry average as no data exists.
  • Unable to calculate PE ratio for Esperite, we can't compare the value of its earnings to the Netherlands market.
Price based on expected Growth
Does Esperite's expected growth come at a high price?
Raw Data
ENXTAM:ESP PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section 0x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 0 Analysts
Not available
Europe Biotechs Industry PEG Ratio Median Figure of 19 Publicly-Listed Biotechs Companies 1.71x
Netherlands Market PEG Ratio Median Figure of 58 Publicly-Listed Companies 1.21x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Esperite, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Esperite's assets?
Raw Data
ENXTAM:ESP PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-06-30) in EUR Not available
ENXTAM:ESP Share Price * ENXTAM (2020-04-08) in EUR €0.04
Europe Biotechs Industry PB Ratio Median Figure of 177 Publicly-Listed Biotechs Companies 3.49x
Netherlands Market PB Ratio Median Figure of 101 Publicly-Listed Companies 1.44x

* Primary Listing of Esperite.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to compare the PB ratio to the industry average as no data exists.

Next steps:

  1. Examine Esperite's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.
  2. When valuing a company like this, investors focus more on how they perceive the size of the opportunity, the company's ability to deliver and scale, and the strength of the team. While we are not analysing this type of data at the moment, if you don’t know where to start, we recommend reading through Esperite's regulatory filings and announcements.
  3. Show me more potentially undervalued companies in the Biotechs industry
  4. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Value checks
We assess Esperite's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Esperite has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

ESP Future Performance

 How is Esperite expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Esperite has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.

Show me the analysis anyway

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
20.7%
Expected Biotechs industry annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Esperite expected to grow at an attractive rate?
  • Unable to compare Esperite's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
  • Unable to compare Esperite's earnings growth to the Netherlands market average as no estimate data is available.
  • Unable to compare Esperite's revenue growth to the Netherlands market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
ENXTAM:ESP Future Growth Rates Data Sources
Data Point Source Value (per year)
Europe Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 20.7%
Europe Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 17.1%
Netherlands Market Earnings Growth Rate Market Cap Weighted Average 13.5%
Netherlands Market Revenue Growth Rate Market Cap Weighted Average 5.2%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
ENXTAM:ESP Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (1 year ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
All numbers in EUR Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
ENXTAM:ESP Past Financials Data
Date (Data in EUR Millions) Revenue Cash Flow Net Income *
2018-06-30 14 -5 -19
2018-03-31 15 -4 -16
2017-12-31 17 -4 -13
2017-09-30 18 -2 -11
2017-06-30 20 0 -9
2017-03-31 23 0 -9
2016-12-31 26 1 -8
2016-09-30 27 1 -8
2016-06-30 28 0 -7
2016-03-31 28 0 -7
2015-12-31 28 0 -7
2015-09-30 28 0 -7

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Unable to determine if Esperite is high growth as no earnings estimate data is available.
  • Unable to determine if Esperite is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
ENXTAM:ESP Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (1 year ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below

All data from Esperite Company Filings, last reported 1 year ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

ENXTAM:ESP Past Financials Data
Date (Data in EUR Millions) EPS *
2018-06-30 -0.92
2018-03-31 -0.93
2017-12-31 -0.93
2017-09-30 -0.83
2017-06-30 -0.72
2017-03-31 -0.76
2016-12-31 -0.81
2016-09-30 -0.74
2016-06-30 -0.66
2016-03-31 -0.68
2015-12-31 -0.70
2015-09-30 -0.69

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Esperite will efficiently use shareholders’ funds in the future without estimates of Return on Equity.

Next steps:

  1. Examine Esperite's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.
  2. Esperite's future outlook can be gauged by looking at industry trends and market size, and determining how well-positioned the company is compared to its competitors. Take a look at other high-growth Pharmaceuticals & Biotech companies here
  3. Esperite's competitive advantages and company strategy can generally be found in its financial reports archived here.
  4. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Future performance checks
We assess Esperite's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Europe market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Europe market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Esperite has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

ESP Past Performance

  How has Esperite performed over the past 5 years?

  • Esperite's last earnings update was 283 days ago.
The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Esperite's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Insufficient past earnings data to establish if Esperite's year on year earnings growth rate was positive over the past 5 years.
  • Unable to compare Esperite's 1-year growth to the 5-year average as past earnings data has not been reported.
  • Unable to compare Esperite's 1-year growth to the Europe Biotechs industry average as past earnings data has not been reported.
Earnings and Revenue History
Esperite's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Esperite Company Filings, last reported 1 year ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

ENXTAM:ESP Past Revenue, Cash Flow and Net Income Data
Date (Data in EUR Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-06-30 13.57 -18.72 15.34 0.07
2018-03-31 15.06 -15.72 15.37 0.04
2017-12-31 16.55 -12.72 15.40
2017-09-30 18.20 -10.74 16.58 0.00
2017-06-30 19.85 -8.76 17.76 0.00
2017-03-31 23.05 -8.58 18.70 0.00
2016-12-31 26.25 -8.41 19.64 0.00
2016-09-30 27.28 -7.54 19.58 0.06
2016-06-30 28.31 -6.68 19.52 0.13
2016-03-31 27.91 -6.87 19.47 0.16
2015-12-31 27.52 -7.06 19.42 0.19
2015-09-30 27.78 -6.98 19.83 0.19
2015-06-30 28.04 -6.91 20.24 0.20
2015-03-31 27.83 -5.96 20.31 0.22
2014-12-31 27.61 -5.01 20.38 0.24
2014-09-30 27.72 -3.54 20.41 0.24
2014-06-30 27.84 -2.07 20.44 0.24
2014-03-31 28.83 -2.79 20.85 0.27
2013-12-31 29.81 -3.51 21.26 0.29
2013-09-30 31.56 -9.98 21.76 0.32
2013-06-30 33.31 -16.46 22.27 0.36

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • Unable to establish if Esperite has efficiently used shareholders’ funds last year as no Return on Equity data is available.
  • Unable to establish if Esperite has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as past financial data has not been reported.
  • Unable to establish if Esperite improved its use of capital last year versus 3 years ago (Return on Capital Employed) due to insufficient past data.
X
Past performance checks
We assess Esperite's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Esperite has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

ESP Health

 How is Esperite's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Esperite's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Unable to compare short term assets to short term liabilities as Esperite has not reported sufficient balance sheet data.
  • Unable to establish if Esperite's long term commitments exceed its cash and other short term assets as Esperite has not reported sufficient balance sheet data.
Balance sheet
This treemap shows a more detailed breakdown of Esperite's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Unable to establish if Esperite has a high level of physical assets or inventory without balance sheet data.
  • Esperite has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Esperite Company Filings, last reported 1 year ago.

ENXTAM:ESP Past Debt and Equity Data
Date (Data in EUR Millions) Total Equity Total Debt Cash & Short Term Investments
2018-06-30 -3.02 4.55 1.34
2018-03-31 -3.02 4.55 1.34
2017-12-31 0.97 3.79 0.69
2017-09-30 0.97 3.79 0.69
2017-06-30 7.17 5.28 0.73
2017-03-31 7.17 5.28 0.73
2016-12-31 6.67 3.01 0.39
2016-09-30 6.67 3.01 0.39
2016-06-30 12.94 5.58 0.95
2016-03-31 12.94 5.58 0.95
2015-12-31 15.25 3.09 1.45
2015-09-30 15.25 3.09 1.45
2015-06-30 19.70 4.71 2.51
2015-03-31 19.70 4.71 2.51
2014-12-31 21.29 1.26 2.10
2014-09-30 21.29 1.26 2.10
2014-06-30 25.80 0.00 3.76
2014-03-31 25.80 0.00 3.76
2013-12-31 26.77 0.00 8.56
2013-09-30 26.77 0.00 8.56
2013-06-30 27.04 0.00 5.27
  • Esperite has no debt.
  • Esperite had no debt 5 years ago.
  • Esperite has no debt, it does not need to be covered by operating cash flow.
  • Esperite has no debt, therefore coverage of interest payments is not a concern.
X
Financial health checks
We assess Esperite's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Esperite has a total score of 4/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

ESP Dividends

 What is Esperite's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Esperite dividends.
If you bought €2,000 of Esperite shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Esperite's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Esperite's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
ENXTAM:ESP Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 1.1%
Netherlands Market Average Dividend Yield Market Cap Weighted Average of 62 Stocks 4.9%
Netherlands Minimum Threshold Dividend Yield 10th Percentile 1.7%
Netherlands Bottom 25% Dividend Yield 25th Percentile 2.6%
Netherlands Top 25% Dividend Yield 75th Percentile 7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

ENXTAM:ESP Past Annualized Dividends Data
Date (Data in €) Dividend per share (annual) Avg. Yield (%)
2014-04-01 0.000 0.000
2013-08-20 0.000 0.000
2013-04-02 0.000 0.000
2013-03-19 0.000 0.000
2012-05-16 0.080 3.019
2011-04-06 0.070 1.585
2011-03-22 0.070 1.288
2010-04-14 0.060 1.136
2010-03-22 0.060 1.043

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Esperite has not reported any payouts.
  • Unable to verify if Esperite's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Esperite's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Esperite has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Esperite's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1.7%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Esperite afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Esperite has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

ESP Management

 What is the CEO of Esperite's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Frédéric Amar
COMPENSATION €510,000
AGE 55
TENURE AS CEO 6.1 years
CEO Bio

Mr. Frédéric A. Amar has been Chief Executive Officer and Executive Director of Esperite N.V. (Formerly Cryo-Save Group N.V.) since March 19, 2014 and served as its Non Executive Director since November 2013. Mr. Amar served as a Non-Executive Director at Cryo-Save Group N.V. until March 19, 2014. Mr. Amar has a strong scientific background and a successful track record creating and managing companies. He founded ATelecom S.A. in November 2011 in 1995. He also founded Salveo Biotechnology S.A. in November 2011. Mr. Amar holds a degree in Crystallography and a degree in Pharmacy (Pharm.D.) from the Université de Pharmacie of Marseille.

CEO Compensation
  • No earnings data for Esperite, not possible to compare to compensation.
  • Frédéric's remuneration is lower than average for companies of similar size in Netherlands.
Management Team

Frédéric Amar

TITLE
CEO & Executive Director
COMPENSATION
€510K
AGE
55
TENURE
6.1 yrs

Henk Hakvoort

TITLE
Finance Director

Deborah Woodford

TITLE
Accounting Manager

Karol Kindy

TITLE
HR Manager

Ramesh Bhonde

TITLE
Chief Technical Officer of Indian region

Samuel Amar

TITLE
Head of IT

Xi Tong Li

TITLE
Head of Bioinformatics

Gunther Ceusters

TITLE
Chief Operating Officer of CryoSave

Gilbert Verhoef

TITLE
Finance & Tax Manager

Aurelie Martin

TITLE
Genetics Product Manager
Board of Directors Tenure

Average tenure and age of the Esperite board of directors in years:

5.8
Average Tenure
62.5
Average Age
  • The tenure for the Esperite board of directors is about average.
Board of Directors

Gert-Jan van der Marel

TITLE
Chairman
COMPENSATION
€58K
AGE
71
TENURE
5.5 yrs

Frédéric Amar

TITLE
CEO & Executive Director
COMPENSATION
€510K
AGE
55
TENURE
6.1 yrs

Ronald H. Lorijn

TITLE
Non-Executive Director
COMPENSATION
€49K
AGE
68
TENURE
9.9 yrs

Paolo Revoltella

TITLE
Member of the Scientific Advisory Board

Vincent M. Borgeot

TITLE
Non-Executive Director
COMPENSATION
€43K
AGE
57
TENURE
4.8 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month open market individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
X
Management checks
We assess Esperite's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Esperite has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

ESP News

Simply Wall St News

How Much Of Esperite N.V. (AMS:ESP) Do Insiders Own?

Insider Ownership Of Esperite The definition of company insiders can be subjective, and does vary between jurisdictions. … General Public Ownership The general public, who are mostly retail investors, collectively hold 84% of Esperite shares. … Private Company Ownership It seems that Private Companies own 5.5%, of the ESP stock.

Simply Wall St -

What Kind Of Shareholder Owns Most Esperite N.V. (AMS:ESP) Stock?

Large companies usually have institutions as shareholders, and we usually see insiders owning shares in smaller companies. … Esperite is not a large company by global standards. … institutions don't own many shares in the company

Simply Wall St -

Easy Come, Easy Go: How Esperite Shareholders Torched 95% Of Their Cash

Esperite isn't currently profitable, so most analysts would look to revenue growth to get an idea of how fast the underlying business is growing. … Generally speaking, companies without profits are expected to grow revenue every year, and at a good clip. … That's because fast revenue growth can be easily extrapolated to forecast profits, often of considerable size.

Simply Wall St -

Can We See Significant Insider Ownership On The Esperite N.V. (AMS:ESP) Share Register?

As Nassim Nicholas Taleb said, 'Don’t tell me what you think, tell me what you have in your portfolio.'. … Esperite is not a large company by global standards. … Our analysis of the ownership of the company, below, shows that.

Simply Wall St -

Is Esperite NV's (AMS:ESP) CEO Pay Justified?

How Does Frederic Amar's Compensation Compare With Similar Sized Companies. … According to our data, Esperite NV has a market capitalization of €5.6m, and pays its CEO total annual compensation worth €510k. … We examined a group of similar sized companies, with market capitalizations of below €177m

Simply Wall St -

Who Are The Major Shareholders In Esperite NV. (AMS:ESP)?

Check out our latest analysis for Esperite ENXTAM:ESP Ownership_summary Mar 30th 18 Institutional Ownership Due to the big order sizes of institutional investors, a company's shares can experience large, one-sided momentum, driven by high volume of shares removed from, or injected into, the market. … Private Company Ownership Potential investors in ESP should also look at another important group of investors: private companies, with a stake of 11.44%, who are primarily invested because of strategic and capital gain interests. … Thus, potential investors should look into these business relations and check how it can impact long-term shareholder returns.Next Steps: With a low level of institutional ownership, investors in ESP need not worry about non-fundamental factors such as ownership structure causing large impact on stock prices.

Simply Wall St -

Why You Need To Look At This Factor Before Buying Esperite NV. (AMS:ESP)

ESP, with its market capitalisation of €9.41M, is a small-cap stock, which generally have higher beta than similar companies of larger size. … An asset-heavy company tends to have a higher beta because the risk associated with running fixed assets during a downturn is highly expensive. … As a result, the company may be less volatile relative to broad market movements, compared to a company of similar size but higher proportion of fixed assets.

Simply Wall St -

ESP Company Info

Description

Esperite N.V., together with its subsidiaries, operates as a regenerative and predictive medicine company in the Netherlands, Spain, Italy, Switzerland, and internationally. It operates through four segments: Stem Cell, The Cell Factory, Genoma, and Other. The company collects, processes, and stores human adult stem cells from the umbilical cord blood and the umbilical cord. It also provides proteomics and genomics predictive medicines; and implements its proprietary technology for clinical grade production of autologous mesenchymal and stromal stem cells. In addition, it develops AGAATA, a diagnostic system based on the next generation sequencing technology, as well as allows laboratories to perform their own genetic analysis with the bioinformatics and methods developed by Genoma. The company’s products portfolio includes Tranquility, a non-invasive prenatal test; and Cryosave’s whole genome sequencing, carrier screening tests, and other products. Further, it engages in biobanking cord blood and cord tissue stem cells business. The company was formerly known as Cryo-Save Group N.V. and changed its name to Esperite N.V. in July 2014. Esperite N.V. was founded in 2000 and is headquartered in Amsterdam, the Netherlands.

Details
Name: Esperite N.V.
ESP
Exchange: ENXTAM
Founded: 2000
€1,831,464
52,327,548
Website: http://www.esperite.com
Address: Esperite N.V.
Herengracht 282,
Amsterdam,
Noord-Holland, 1016 BX,
Netherlands
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
ENXTAM ESP Ordinary Shares Euronext Amsterdam NL EUR 06. Nov 2007
DB 5C1A Ordinary Shares Deutsche Boerse AG DE EUR 06. Nov 2007
LSE 0OMG Ordinary Shares London Stock Exchange GB EUR 06. Nov 2007
BATS-CHIXE ESPA Ordinary Shares BATS 'Chi-X Europe' GB EUR 06. Nov 2007
Number of employees
Current staff
Staff numbers
0
Esperite employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2020/04/08 22:05
End of day share price update: 2020/04/08 00:00
Last earnings filing: 2019/06/30
Last earnings reported: 2018/06/30
Last annual earnings reported: 2017/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.